Looks like you’re on the UK site. Choose another location to see content specific to your location
Thermo Fisher Scientific launches four new cancer research assays
Thermo Fisher Scientific has announced the launch of four new next-generation sequencing cancer research assays.
The new Oncomine products are designed to support immune response analysis of the tumour microenvironment, as well as the interrogation of BRCA 1-2 genes and liquid biopsy research using cell-free DNA from breast and colon cancer samples.
Among these new offerings is the Oncomine Immune Response Research Assay, a very low-sample input gene expression assay for use in Ion Torrent next-generation sequencing platforms targeting low-expressing transcripts derived from FFPE samples that offers several benefits.
Also launching are the Oncomine BRCA Research Assay, Oncomine Breast cfDNA Assay and the Oncomine Colon cfDNA Assay, which can facilitate genetic research and disease diagnosis.
Joydeep Goswami, president of clinical sequencing for Thermo Fisher Scientific, said: "As researchers broaden their efforts to push discovery in promising areas of cancer research, we also are driven to enable their work through development of sophisticated analysis tools."
All of these new assays were recently showcased at the Association of Molecular Pathology annual meeting.
With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard